News Analysis
One of China’s biggest drugmakers recently said that it overstated its assets by $4.4 billion, calling into question the quality and standard of accounting at Chinese listed companies.
A $4 Billion Error, and Cold Facts About Investing in China
One of China’s biggest drugmakers said it overstated its assets by $4.4 billion, calling into question the quality and standard of accounting at Chinese listed companies.
An investor monitors stock prices at a securities company in Hangzhou, Zhejiang Province on Dec. 3, 2018. STR/AFP/Getty Images
|Updated:
Fan Yu
Author
Fan Yu is an expert in finance and economics and has contributed analyses on China's economy since 2015.
